Chimeric Antigen Receptor (CAR) T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers. Solid tumors, which account for around 90% of ...

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing.

Please provide your email address to receive an email when new articles are posted on . Allogeneic cell therapies help overcome challenges of autologous products, such as manufacturing complexity and ...

A Russian man had a hulking tumor the size of his head surgically removed from his neck after more than a decade of using failed home remedies in hopes it would “go away on its own.” The 65-year-old ...

LOUISVILLE, Ky. (WDRB) -- Researchers at the Indiana University School of Medicine are developing new ways to fight tumors and aggressive forms of cancer—such as triple-negative breast cancer, ...

Objective: To analyze the evolution of patient/tumor characteristics and treatments for GCTB in the knee in Brazil over 30 years and assess changes in local recurrence rates. Methods: Retrospective ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing ...

At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...

Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months ...

EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced the presentation of detailed positive results from Part 1 of the global Phase 3 MANEUVER ...

Merck KGaA said pimicotinib, an orally administered inhibitor for tenosynovial giant cell tumor, delivered positive results in a late-phase study. The German life-sciences and electronics company said ...

Change in T2-weighted signal intensity, change in tumor volume, and exposure-response analysis in the RINGSIDE phase 2 study of varegacestat in patients with desmoid tumors. This is an ASCO Meeting ...